When you buy through our links, Business Insider may earn an affiliate commission. Learn more Flying with a cat is stressful, but one of the best airline-approved cat carriers can make it easier ...

Cytokinetics' aficamten shows strong potential in the $3B U.S. oHCM market, despite competition from Bristol Myers’ Camzyos. Stifel sets a $80 price target, highlighting catalysts expected over ...

Stifel analyst James Condulis writes Cytokinetics’ aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

However, Condulis cites a challenging path for the company to differentiate EDG-7500 from aficamten, a rival HCM candidate from Cytokinetics (CYTK). Meanwhile, despite recent positive trial data ...

A Maine coon cat named Mittens became an accidental jetsetter this month when her cage was overlooked in a plane cargo hold and she made three trips in 24 hours between New Zealand and Australia.

Other investigational procedures while participating in this study are not permitted. Since completion of a previous trial of aficamten has: Developed new-onset paroxysmal or permanent atrial ...

Learn more The best outdoor cat houses help keep felines warm and dry in the worst winter conditions and protect them from extreme heat when temperatures spike. During the winter, cats that live ...

Aficamten is under clinical development by Cytokinetics and currently in Pre-Registration for Hypertrophic Cardiomyopathy. According to GlobalData, Pre-Registration drugs for Hypertrophic ...

As experts continue monitoring and surveying the environment and the nation’s food supply for H5N1 bird flu, a rash of dead cats has many officials on edge. From pet cats in Los Angeles County ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline is ...